Upcoming and recently listed IPOs with Guggenheim Securities, LLC as underwriter, lead manager or listing sponsor.
Names are taken from each deal's exchange listing where the exchange publishes them, and otherwise read from the underwriting section of the company's own SEC prospectus. Euronext listings contribute the listing sponsor, a related but distinct role. See each company's page for the full, unedited text and its source.
DiscoverIPO is tracking 2 upcoming IPOs with underwriter Guggenheim Securities, LLC. Every row links to the original filing or exchange calendar entry it came from, and this page updates automatically as new filings arrive.
terms not yet disclosed
terms not yet disclosed
| Company | Industry | Country | Price range | Offer size | Expected | Status | Source |
|---|---|---|---|---|---|---|---|
| Holtec Nuclear CorpHNUC | Construction - Special Trade Contractors | United States | terms not yet disclosed | Not yet set | Filed with SEC | SEC EDGAR | |
| Tailored Brands, Inc. / DEMENW | Retail-Apparel & Accessory Stores | United States | terms not yet disclosed | Not yet set | Filed with SEC | SEC EDGAR | |
3 companies have listed with underwriter Guggenheim Securities, LLC in the last 6 months. 2 of them have a disclosed offer size, the largest being Latigo Biotherapeutics, Inc. at $313M. The most recent listing date on record is Aug 6, 2026. All listed on NASDAQ.
| Company | Industry | Country | Price range | Offer size | Listed | Status | Source |
|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc.BLSM | Pharmaceutical Preparations | United States | $15.00 – $17.00 | $144M | Aug 6, 2026 | Listed | NYSE |
| Latigo Biotherapeutics, Inc.LTGO | Pharmaceutical Preparations | United States | $16.00 – $18.00 | $313M | Aug 6, 2026 | Listed | NYSE |
| Scribe Therapeutics, Inc. | Biological Products, (No Diagnostic Substances) | United States | $15.00 | — | Jul 27, 2026 | Priced | SEC EDGAR |
A plain-language summary of that week's filings, pricings, and listings — sent every Monday. No spam, unsubscribe anytime.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy